Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130927 | 0.88 | LSS (0.90) | LSSSIGMAR1PPARGMAPTALDH1A1 | |
| SCHEMBL3868846 | 0.85 | LSS (0.98) | LSSPPARGMAPTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL27587869 | 0.80 | LSS (0.62) | LSSSIGMAR1MAPTALDH1A1LMNA | |
| SCHEMBL9129519 | 0.80 | LSS (0.76) | LSSSIGMAR1PPARGMAPTALDH1A1 | |
| SCHEMBL270734 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MAPTTDP1LMNAKMT2A | |
| SCHEMBL9129012 | 0.78 | LSS (0.72) | LSSSIGMAR1PPARGMAPTALDH1A1 | |
| SCHEMBL6034608 | 0.77 | SIGMAR1 (0.83) | SIGMAR1MAPTTDP1LMNAKMT2A | |
| SCHEMBL1241906 | 0.77 | HRH3 (0.78) | TDP1ALDH1A1TNIK | |
| SCHEMBL29019309 | 0.76 | ALDH1A1 (0.84) | SIGMAR1PPARGTDP1ALDH1A1LMNA | |
| SCHEMBL3913390 | 0.76 | TAAR1 (0.72) | PPARGTDP1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | LSS 2955/4885SIGMAR1 135/4885PPARG 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.